論文・技術情報追加のお知らせ

1. Abemaciclib-associated kidney injuries: A retrospective analysis of the United States Food and Drug Administration adverse events reporting system.

アベマシクリブの腎障害リスクを示す副作用分析

対象DB：FAERS

2. Sodium zirconium cyclosilicate-associated adverse events: An analysis of the FAERS database.

SZCの副作用シグナル35件、安全性評価に貢献

対象DB：FAERS

3. Levodopa-induced motor complications associated with benserazide and carbidopa in Parkinson's disease: a disproportionality analysis of the FAERS database.

BSZは運動合併症のリスクを増加させ、CDは「ウェアリングオフ」に関連

対象DB：FAERS

4. Drugs Associated with Floppy Iris Syndrome: A Real-World Population-Based Study: Drugs Associated with Floppy Iris Syndrome.

IFISに関連する薬物として、男性と女性で異なるリスクを示す

対象DB：FAERS

5. Risk comparison of adverse reactions between gemcitabine monotherapy and gemcitabine combined with albumin-bound paclitaxel in pancreatic cancer: insights from the FDA Adverse Event Reporting System (FAERS) database.

AG治療は、G治療よりも高い副作用リスクを示す

対象DB：FAERS

6. Comparative analysis of CDKI-related adverse events in older patients: a real-world data from the FDA adverse event reporting system database.

高齢者におけるCDKI使用で予期しない副作用が確認

対象DB：FAERS

7. A disproportionality analysis of adverse events associated with loop diuretics in the FDA Adverse Event Reporting System (FAERS).

ループ利尿薬の新たな副作用として、ビタミンB1欠乏や免疫反応などが特定

対象DB：FAERS

8. Disproportionality analysis of post-marketing safety concerns associated with selumetinib in the FDA adverse event reporting system.

セルメチニブ治療による副作用の分析、特に心臓、眼、皮膚の毒性が顕著

対象DB：FAERS

9. Unveiling cardiovascular and respiratory toxicities with monoclonal antibodies in multiple myeloma: disproportionality analysis from the FDA Adverse Event Reporting System.

MM治療におけるモノクローナル抗体使用による心血管および呼吸器系の予期せぬ副作用

対象DB：FAERS

10. Data Mining of the FDA Adverse Event Reporting System and Animal Experiments for Assessment of Rhabdomyolysis Risk Associated with Lipid-lowering Drugs.

スタチンとフィブラート併用による横紋筋融解症リスク増加

対象DB：FAERS

11. Exploring Temporal and Spatial Characteristics of Serious Adverse Event Reports Following COVID-19 Bivalent Vaccines.

COVID-19二価ワクチンの副作用地域差と時間的傾向分析

対象DB：FAERS,VAERS

12. Vitiligo associated with type 2 immune inhibitors: FAERS analysis and literature review.

タイプ2免疫反応抑制薬と白斑の関連性確認

対象DB：FAERS

13. Adverse event profile of crizotinib in real-world from the FAERS database: a 12-year pharmacovigilance study.

クリゾチニブの副作用に新たな重篤な影響が確認

対象DB：FAERS

14. Hemorrhage risk associated with triple antithrombotic therapy: a focused real-world pharmacovigilance disproportional analysis study.

TATは出血リスクが高く、特にリバーロキサバンに注意が必要

対象DB：FAERS

15. Reported psychiatric adverse events among isotretinoin users: Monitoring priorities from a 20-year FDA Adverse Event Reporting System database study.

イソトレチノイン治療中の精神障害には特に注意が必要

対象DB：FAERS

16. Adverse Reactions to Ginkgo biloba Medicinal Products Released in European Countries.

ギンコビロバ製品の副作用、欧州で報告

対象DB：EudraVigilance

17. Comparative Safety Profiles of Biosimilars vs. Originators Used in Rheumatology: A Pharmacovigilance Analysis of the EudraVigilance Database.

バイオシミラーは参照製品と同等の安全性を示し、医療費削減に貢献

対象DB：EudraVigilance

18. Narrative Search Engine for Case Series Assessment Supported by Artificial Intelligence Query Suggestions.

AI支援型検索エンジンは、シグナル評価時に有効な追加情報の検索を支援

対象DB：VigiBase

19. Effects of inpatient and outpatient cardiac rehabilitation on the 5-year prognosis in patients with acute myocardial infarction.

入院中の心臓リハで心筋梗塞患者の予後改善

対象DB：DPC

20. Diabetes with COVID-19 was a significant risk factor for mortality, mechanical ventilation, and renal replacement therapies: A multicenter retrospective study in Japan.

糖尿病患者はCOVID-19で重症化リスク高い

対象DB：DPC

21. Association between early-phase opioid use and outcomes in extremely preterm infants: A nationwide study.

早期オピオイド使用は死亡や脳内出血に関連せず、脳室周囲白質軟化症は減少

対象DB：DPC

22. Increased early complication rates following total hip arthroplasty in rheumatoid arthritis patients based on a Japanese nationwide medical claims database study.

RA患者のTHA後、脱臼・再手術リスク増

対象DB：DPC

23. Projection of future demand for non-cancerous gastrointestinal surgery in Japan: challenges and workforce planning in an aging society.

高齢化で消化器外科手術の需要減、労働力不足懸念

対象DB：NDB

24. Impact of weight loss on obesity-related complications and direct healthcare costs in Japan: A modelling study.

日本における減量は合併症と医療費を削減

対象DB：MDV

25. A retrospective cohort study assessing medication coverage in patients with prostate cancer prescribed luteinizing hormone releasing hormone (LHRH) agonists in England.

LHRHアゴニストの投与遅延がPC管理に影響

対象DB：CPRD

26. Real-World Comparisons Between Glucagon-Like Peptide-1 Receptor Agonists and Other Glucose-Lowering Agents in Type 2 Diabetes: Retrospective Analyses of Cardiovascular and Economic Outcomes in England.

GLP-1RAは高リスクT2DでMACEと費用を低減

対象DB：CPRD

27. Identification of heart failure subtypes using transformer-based deep learning modelling: a population-based study of 379,108 individuals.

深層学習で心不全を7つの亜型に分類

対象DB：CPRD

28. Deprescribing of preventive medications in palliative care patients living with multiple long-term conditions in their final 12 months of life: A retrospective cohort Clinical Practice Research Datalink study.

終末期患者の予防薬中止はまれ

対象DB：CPRD

29. Long-term event rates, risk factors, and treatment pattern in 1.4 million individuals qualifying for dual blood pressure lowering therapy.

二剤併用療法は心血管イベントを抑制

対象DB：CPRD

30. Systemic inflammation prevalence in patients with atherosclerotic cardiovascular disease and chronic kidney disease: a population-based study using a nationwide primary care database in Spain.

ASCVD患者の全身性炎症が高頻度に認められた

対象DB：THIN

31. Intravitreal vascular endothelial growth factor inhibitors and cardiovascular adverse drug reactions: Added value of the data of the French pharmacovigilance spontaneous reporting assessment.

I-VEGF投与後、心血管有害事象の報告あり

対象DB：FPVD

32. Vaccines and the risk of Guillain-Barre syndrome: A French pharmacovigilance analysis.

ワクチン接種後数週間以内にGBSの報告あり

対象DB：FPVD